Over $4 Million Has Been Granted to Fund Genetic Mitochondrial Disease Research

The United States government has awarded a grant of over $4 million to fund research into genetic mitochondrial diseases. The three-year grant was given to the Children’s Hospital of Philadelphia for studies linked to NeuroVive’s NCP015 program focused on genetic mitochondrial diseases. For more detailed information, you can view the source press release here, at Bio Space.

About Genetic Mitochondrial Disorders

Genetic mitochondrial disorders are a group of conditions that affect how the mitochondria (a part of the cell involved in making energy) functions. Since mitochondria are present throughout the body, almost any area can be affected and there is a large range of possible symptoms. Some of the more commonly affected areas include the brain, muscles, nerves, eyes, ears, kidney, and liver. This range of symptoms can make mitochondrial disorders difficult to diagnose, and many people may go years without reaching a diagnosis.

Genetic mitochondrial disorders can be the result of a genetic alteration that prevents the mitochondria from functioning properly, and leads to reduced energy production. As a result, the body may not have enough energy and this can lead to symptoms associated with the disorders.

About the Research Grant

A three-year grant totalling $4,090,218 USD has been awarded by the US Department of Defence, Office of the Congressionally Directed Medical Research Programs to researchers working at the Children’s Hospital of Philadelphia (CHOP). The grant is intended to fund research linked to NeuroVive Pharmaceutical’s NVP015 program that is investigating genetic mitochondria diseases.

This research program aims to develop a drug for the treatment of acute energy crises in patients with genetic mitochondrial diseases. The research team plans to investigate compounds for their potential therapeutic use, before submitting Investigational New Drug candidate to the US Food and Drug Administration. The drug may then be further investigated in Phase 1 clinical trials.

For more detailed information about these plans, you can view the source press release here.

Anna Hewitt

Anna Hewitt

Anna is from England and recently finished her undergraduate degree. She has an interest in medicine and enjoys writing. In her spare time she likes to cook, hike, and hang out with cats.

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email
Close Menu